Innate Immune Responses in Chronic Obstructive Pulmonary Disease (COPD) Patients

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

We hypothesize that ongoing and more severe airway inflammation in COPD may result from the impairment in activation of innate immune response

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mahidol University
• Collaborator: National Science and Technology Development Agency, Thailand
• Treatments: Budesonide

Criteria

Inclusion Criteria:

• clinical diagnosis of COPD or asthma

• a ratio of prebronchodilator FEV1 to forced vital capacity (FVC) equal to or less than 0.70

• postbronchodilator FEV1 > or = 50% predicted

Exclusion Criteria:

• Exacerbation

• systemic corticosteroids

• DM, HIV and autoimmune disease

• immunosuppressive therapy